Search research articles
Contact Us
Filters
Showing results (231-240 of 386) with videos related to
Page
of 39
Sort By:
Urologic Oncology
|
August 6, 2011
A non-comparative randomized phase II study of 2 doses of ATN-224, a copper/zinc superoxide dismutase inhibitor, in patients with biochemically recurrent hormone-naïve prostate cancer
Jianqing Lin, Marianna Zahurak, Tomasz M Beer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 1, 2009
A phase I dose-finding study of 5-azacytidine in combination with sodium phenylbutyrate in patients with refractory solid tumors
Jianqing Lin, Jill Gilbert, Michelle A Rudek, et al.
The Oncologist
|
September 14, 2012
Pretreatment neutrophil-to-lymphocyte ratio in metastatic castration-resistant prostate cancer patients treated with ketoconazole: association with outcome and predictive nomogram
Daniel Keizman, Maya Gottfried, Maya Ish-Shalom, et al.
Cancer Chemotherapy and Pharmacology
|
February 25, 2025
A phase 1 study of the combination of BH3-mimetic, navitoclax, and mTORC1/2 inhibitor, vistusertib, in patients with advanced solid tumors
Susan C Scott, Anna Farago, W Victoria Lai, et al.
Cancer Research and Treatment
|
March 13, 2015
Is there a "Trial Effect" on Outcome of Patients with Metastatic Renal Cell Carcinoma Treated with Sunitinib?
Daniel Keizman, Keren Rouvinov, Avishay Sella, et al.
European Urology
|
December 24, 2014
A national multicenter phase 2 study of prostate-specific antigen (PSA) pox virus vaccine with sequential androgen ablation therapy in patients with PSA progression: ECOG 9802
Robert S DiPaola, Yu-Hui Chen, Glenn J Bubley, et al.
The Prostate
|
September 3, 2010
Disulfiram is a DNA demethylating agent and inhibits prostate cancer cell growth
Jianqing Lin, Michael C Haffner, Yonggang Zhang, et al.
European Urology Oncology
|
May 22, 2021
Phase 3 Randomized Controlled Trial of Androgen Deprivation Therapy with or Without Docetaxel in High-risk Biochemically Recurrent Prostate Cancer After Surgery (TAX3503)
Michael J Morris, Jose Mauricio Mota, Kristine Lacuna, et al.
The Prostate
|
March 23, 2021
What are survivorship care plans failing to tell men after prostate cancer treatment?
Youngjee Choi, Katherine C Smith, Aishwarya Shukla, et al.
Clinical Genetics
|
January 12, 2010
Phenotypic variability, neurological outcome and genetics background of 6-pyruvoyl-tetrahydropterin synthase deficiency
V Leuzzi, C A Carducci, C L Carducci, et al.
Page
of 39
Search research articles
Search
Showing results (231-240 of 386) with videos related to
Sort By:
Page
of 39
Urologic Oncology
|
August 6, 2011
A non-comparative randomized phase II study of 2 doses of ATN-224, a copper/zinc superoxide dismutase inhibitor, in patients with biochemically recurrent hormone-naïve prostate cancer
Jianqing Lin, Marianna Zahurak, Tomasz M Beer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 1, 2009
A phase I dose-finding study of 5-azacytidine in combination with sodium phenylbutyrate in patients with refractory solid tumors
Jianqing Lin, Jill Gilbert, Michelle A Rudek, et al.
The Oncologist
|
September 14, 2012
Pretreatment neutrophil-to-lymphocyte ratio in metastatic castration-resistant prostate cancer patients treated with ketoconazole: association with outcome and predictive nomogram
Daniel Keizman, Maya Gottfried, Maya Ish-Shalom, et al.
Cancer Chemotherapy and Pharmacology
|
February 25, 2025
A phase 1 study of the combination of BH3-mimetic, navitoclax, and mTORC1/2 inhibitor, vistusertib, in patients with advanced solid tumors
Susan C Scott, Anna Farago, W Victoria Lai, et al.
Cancer Research and Treatment
|
March 13, 2015
Is there a "Trial Effect" on Outcome of Patients with Metastatic Renal Cell Carcinoma Treated with Sunitinib?
Daniel Keizman, Keren Rouvinov, Avishay Sella, et al.
European Urology
|
December 24, 2014
A national multicenter phase 2 study of prostate-specific antigen (PSA) pox virus vaccine with sequential androgen ablation therapy in patients with PSA progression: ECOG 9802
Robert S DiPaola, Yu-Hui Chen, Glenn J Bubley, et al.
The Prostate
|
September 3, 2010
Disulfiram is a DNA demethylating agent and inhibits prostate cancer cell growth
Jianqing Lin, Michael C Haffner, Yonggang Zhang, et al.
European Urology Oncology
|
May 22, 2021
Phase 3 Randomized Controlled Trial of Androgen Deprivation Therapy with or Without Docetaxel in High-risk Biochemically Recurrent Prostate Cancer After Surgery (TAX3503)
Michael J Morris, Jose Mauricio Mota, Kristine Lacuna, et al.
The Prostate
|
March 23, 2021
What are survivorship care plans failing to tell men after prostate cancer treatment?
Youngjee Choi, Katherine C Smith, Aishwarya Shukla, et al.
Clinical Genetics
|
January 12, 2010
Phenotypic variability, neurological outcome and genetics background of 6-pyruvoyl-tetrahydropterin synthase deficiency
V Leuzzi, C A Carducci, C L Carducci, et al.
Page
of 39